The global malaria diagnostics market size reached US$ 829.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,383.3 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023 | US$ 829.3 Million |
Market Forecast in 2032 | US$ 1,383.3 Million |
Market Growth Rate (2024-2032) | 5.7% |
Malaria diagnostics refers to the clinical tests conducted to detect the presence of the infection in individuals. Malaria is caused by the bite of an infected female Anopheles mosquito, which leads to the transfer of Plasmodium parasites into the body. Some common symptoms include fever, fatigue, nausea and headaches. The infection is diagnosed through various rapid diagnostics, microscopy and molecular diagnostic tests. These tests use antigen detection and serology techniques using indirect immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA). They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.
The increasing prevalence of malaria across the globe is one of the key factors creating a positive outlook for the market. Malaria is a life-threatening infection that has caused a significant loss of human lives, especially in developing nations. However, rising awareness among the masses regarding the available diagnostic and treatment alternatives for malaria is providing a thrust to the market growth. Healthcare centers and diagnostic laboratories are widely adopting microscopic diagnostics to identify the parasite at different stages and design suitable treatment plans. Additionally, various technological advancements, such as the development of the Quantitative Buffy Coat (QBC) method and peripheral blood smear technique for diagnosing malaria, are acting as other growth-inducing factors. In line with this, the availability of Point-of-Care (POC) diagnostic devices for enhanced accuracy is also contributing to the growth of the market. Other factors, including rising healthcare expenditure capacities of the masses, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
IMARC Group provides an analysis of the key trends in each sub-segment of the global malaria diagnostics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technology and end use.
Breakup by Technology:
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Breakup by End Use:
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Access Bio, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA (Compagnie Merieux Alliance), Bio-Rad Laboratories Inc., Nikon Corporation, Novartis AG, Olympus Corporation, Premier Medical Corporation Pvt. Ltd., Siemens Healthcare GmbH (Siemens AG), Sysmex Corporation and Thermo Fisher Scientific Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Million |
Segment Coverage | Technology, End Use, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Access Bio, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA (Compagnie Merieux Alliance), Bio-Rad Laboratories Inc., Nikon Corporation, Novartis AG, Olympus Corporation, Premier Medical Corporation Pvt. Ltd., Siemens Healthcare GmbH (Siemens AG), Sysmex Corporation and Thermo Fisher Scientific Inc |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global malaria diagnostics market was valued at US$ 829.3 Million in 2023.
We expect the global malaria diagnostics market to exhibit a CAGR of 5.7% during 2024-2032.
The rising adoption of microscopy and molecular diagnostic tests that generally use antigen detection and serology techniques to detect the presence of malaria is primarily driving the global malaria diagnostics market.
The sudden outbreak of the COVID-19 pandemic had led to the growing focus on the diagnosis and treatment of the coronavirus infection, thereby negatively impacting the global market for malaria diagnostics.
Based on the technology, the global malaria diagnostics market has been segregated into microscopy, Rapid Diagnostic Tests (RDTs), and molecular diagnostic tests. Among these, microscopy currently exhibits a clear dominance in the market.
Based on the end use, the global malaria diagnostics market can be bifurcated into hospital, clinics, and diagnostic centers. Currently, clinics hold the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Middle East and Africa currently dominates the global market.
Some of the major players in the global malaria diagnostics market include Abbott Laboratories, Access Bio, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA (Compagnie Merieux Alliance), Bio-Rad Laboratories Inc., Nikon Corporation, Novartis AG, Olympus Corporation, Premier Medical Corporation Pvt. Ltd., Siemens Healthcare GmbH (Siemens AG), Sysmex Corporation, and Thermo Fisher Scientific Inc.